 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...101102103104105106107108109110111...123124» |
- Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Computational discovery and preclinical validation of therapeutic leads with novel MOAs for hepatocellular carcinoma and pancreatic ductal adenocarcinoma (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_2444;
In subsequent in vivo efficacy studies using two HCC patient-derived xenograft (PDX) tumor models, TXR-311 showed excellent tolerability and displayed significant tumor growth inhibition efficacy compared to vehicle-treated controls. TXR-311 presents a first-in-class lead for further development as a potential HCC therapy.
- Lenvima (lenvatinib) / Eisai, Merck (MSD), E7090 / Eisai
Targeting fibroblast growth factor (FGF) signals induced type I IFN regulated response and Immunogenic cell death (ICD) markers in tumor cells with activated FGF signals (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_2389;
Tumor FGF signal inhibition by LEN and E7090 may enhance antitumor immune response in the TMEs of that were immune suppressive with activated FGF signals. Further analyses will be warranted.
- Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
Comprehensive analysis for genomic features of stem cell-like hepatocellular carcinoma (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_2037;
We identified subtype-specific serum and tissue biomarkers for the stem cell-like subtypes and precise therapeutic strategies for each subtype regarding immunotherapy and molecular-targeted treatment. Our findings may offer the theoretical foundation of biomarker-based clinical trials for new therapeutic approaches to resectable early-stage HCC patients.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib (LEN) for the Treatment of Anaplastic Thyroid Cancer (ATC) () - May 15, 2020 - Abstract #ENDOI2020ENDO-I_117;
P2
Additionally, in Study 208, all pts were Japanese and tumor assessments were conducted more frequently (4- vs 6-weekly). These differences may have contributed to the observed variation in results between the 2 studies.
- |||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical: Significant activity of Lenvatinib and Pembro #Immunotherapy for #HCC patients! BUT also concerning toxicity I believe (grade ≥3, 67%; grade ≥4, 4% TRAES). @EisaiUS #ASCO20 https://t.co/lXcLHluELM (Twitter) - May 15, 2020
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Trial primary completion date, Metastases: Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma (clinicaltrials.gov) - May 14, 2020
P1, N=20, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
These differences may have contributed to the observed variation in results between the 2 studies. Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2020 --> Oct 2019
- |||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical: The @NEJM abstract for Bev/Atezo does not include RR data and it is buried in the text. This is because it is lower than what we would expect for practice changing trial at 27%-not too far off what we saw with lenvatinib albeit different trials/different populations #LiverCancer (Twitter) - May 14, 2020
- || Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
Clinical, Journal: Skeletal Muscle Loss during Tyrosine Kinase Inhibitor Treatment for Advanced Hepatocellular Carcinoma Patients. (Pubmed Central) - May 14, 2020
No significant differences were observed in median ΔSMI between patients with and without progressive disease (-2.35 and -1.1 cm2/m2/months, respectively), albumin-bilirubin grade 1 and 2 group disease (-1.7 and -1.5 cm2/m2/months, respectively), and relative dose intensity ≤80 and >80 (-1.8 and -1.2 cm2/m2/months, respectively). This report demonstrated that patients receiving TKI treatment experienced a significant loss of skeletal muscle mass regardless of disease progression, hepatic reserve, or which TKI (sorafenib or lenvatinib) they received.
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, Journal: Skeletal Muscle Mass Influences Tolerability and Prognosis in Hepatocellular Carcinoma Patients Treated with Lenvatinib. (Pubmed Central) - May 14, 2020
Decreased skeletal muscle mass is associated with the occurrence of severe AEs and worse TTF and OS. Skeletal muscle mass can be used as a predictive marker for tolerability and prognosis to lenvatinib in patients with HCC.
- |||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, Head-to-Head: Such dark was the picture in first line HCC that any new drug would plan a non inferiority trial (ref- Lenvatinib) .This was a superiority trial with OS/PFS as endpt - Justifies the name of the trial- I M brave 😀 (Twitter) - May 14, 2020
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date: Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) (clinicaltrials.gov) - May 14, 2020
P1, N=400, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Skeletal muscle mass can be used as a predictive marker for tolerability and prognosis to lenvatinib in patients with HCC. Trial completion date: May 2022 --> Dec 2023
- ||| Cyramza (ramucirumab) / Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
I would be reluctant to give Lenvatinib and Ramucirumab given their cleaner VEGF targeting .. I would rather give Rego or Cabo given they are "dirtier" with the latter targeting Met ( one of the drivers of R to VEGF) . No advantage for Sorafenib ( so done) .. (Twitter) - May 13, 2020
- || Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Tecentriq (atezolizumab) / Roche
Also waiting for the data from LEAP002 ( combination of lenvatinib +pembeolizumab), Cosmic 312 ( combination of cabozantinib +Atezolizumab). (Twitter) - May 13, 2020
- | Opdivo (nivolumab) / Ono Pharma, BMS
Review, Journal: Systemic Therapy for Advanced Hepatocellular Carcinoma in an Evolving Landscape. (Pubmed Central) - May 13, 2020
Positioning of these immunotherapies in the landscape may or may not have impacts upon sequencing of all of the available therapies. Further studies are ongoing investigating such sequencing questions, in addition to more novel agents to combat this devastating disease.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] Lenvatinib in hepatocellular carcinoma: QoL surveys and radiological imaging markers predicting clinical outcome in patients with hepatocellular carcinoma treated with lenvatinib as first-line treatment (SULENVA-HCC) () - May 13, 2020 - Abstract #ESMOGI2020ESMO_GI_417;
Legal entity responsible for the study The authors. Funding Has not received any funding.
- [VIRTUAL] Clear cell variant of hepatocellular carcinoma (HCC-CC): A single-center observational study of an uncommon subtype () - May 13, 2020 - Abstract #ESMOGI2020ESMO_GI_367;
Legal entity responsible for the study The authors. Funding Has not received any funding.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet REFLECT trial inclusion criteria () - May 13, 2020 - Abstract #ESMOGI2020ESMO_GI_319;
Legal entity responsible for the study The authors. Funding Has not received any funding.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] LEAP-012: A randomized, double-blind, phase 3 study of pembrolizumab plus lenvatinib in combination with transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma not amenable to curative treatment () - May 13, 2020 - Abstract #ESMOGI2020ESMO_GI_255;
P3
Legal entity responsible for the study Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Funding Funding for this research was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Biomarker, Clinical, Journal: Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma. (Pubmed Central) - May 13, 2020
OPNIC grading might have a potential for easy substitution of mALBI grading. A good nutritional status (OPNIC grade 1) or mALBI grade 1 is the best indication for lenvatinib use, while with an OPNIC grade 3, lenvatinib might be not suitable.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, P3 data, Journal: Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer. (Pubmed Central) - May 7, 2020
P3
This analysis highlights the importance of timely management of lenvatinib toxicities to minimise dose interruptions and maximise lenvatinib efficacy in patients with RR-DTC. CLINICALTRIALS.
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD), Lynparza (olaparib) / Merck (MSD), AstraZeneca
$MRK #ASCO20 New Findings for LYNPARZA® (olaparib) and KEYTRUDA plus LENVIMA® (lenvatinib) (Twitter) - May 7, 2020
- || Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Review, Journal: Multikinase Inhibitor Treatment in Thyroid Cancer. (Pubmed Central) - May 6, 2020
The objective of this review is to give an update on MKI treatment (lenvatinib, sorafenib, sunitinib, cabozantinib, pazopanib, vandetanib) of thyroid cancer, regarding its efficacy and safety profile...The AEs are often more severe in patients with high efficacy of MKIs, which could indicate a correlation. Taken together, the novel therapeutic regimen with MKIs has shown favorable results in otherwise treatment-resistant thyroid cancer.
- Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
THERAPEUTIC EFFICACY AND SAFETY OF LENVATINIB FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA BEYOND PROGRESSION WITH SORAFENIB () - May 4, 2020 - Abstract #DDW2020DDW_5543;
LEN was active and safe as a second/third-line treatment for unresectable HCC. LEN seems to be more effective for HCC patients with better hepatic reserve function or before TKI-resistance is acquired because of partial cross-resistance to SOR
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
PROGNOSTIC IMPACT OF TYROSINE KINASE INHIBITOR SEQUENTIAL TREATMENT INCLUDING LENVATINIB FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA () - May 4, 2020 - Abstract #DDW2020DDW_5538;
The present results showed that TKI sequential therapy that includes LEN as a second- or third-line drugs increased efficacy for improving the prognosis of u-HCC patients. Initiation of TKI therapy in those with better hepatic reserve function (mALBI 1 or 2a, ALBI score ≤–2.27) have a better possibility of undergoing sequential treatment
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
THE SAFETY OF ENDOSCOPY AMONG PATIENTS ON ANTIANGIOGENIC AGENTS: A SINGLE CENTER EXPERIENCE () - May 4, 2020 - Abstract #DDW2020DDW_5154;
The risk likely is attributed to the advanced disease of these patients. However, future prospective studies are needed to confirm this finding.
- || Lenvima (lenvatinib) / Eisai, Merck (MSD), Sutent (sunitinib) / Pfizer, Nexavar (sorafenib) / Bayer, Amgen
Clinical, Retrospective data, Journal, HEOR, Real-World Evidence: Real-World Treatment Patterns Among Patients Initiating Small Molecule Kinase Inhibitor Therapies for Thyroid Cancer in the United States. (Pubmed Central) - May 2, 2020
Median treatment duration results suggested potential benefit of SMKI in second-line therapy. SMKI treatment after first-line failure may be considered for appropriately selected patients.
- |||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
FDA event: FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis https://t.co/yNP0cu8Iiu (Twitter) - May 2, 2020
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Weight-based dosing of lenvatinib for advanced hepatocellular carcinoma. (Pubmed Central) - May 2, 2020
SMKI treatment after first-line failure may be considered for appropriately selected patients. No abstract available
- Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
[VIRTUAL] Analysis of bleeding risk with concurrent treatment of VEGFR tyrosine kinase inhibitors (TKIs) and factor Xa inhibitors. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_5014;
Concurrent treatment of VEGFR TKI and factor Xa inhibitors is associated with significantly increased bleeding risk when compared with factor Xa inhibitors alone in metastatic cancer patients. Research Funding: None
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] Planned drug holidays during treatment with lenvatinib for radioiodinerefractory differentiated thyroid cancer (RR-DTC): A retrospective study. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4701;
- Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
[VIRTUAL] Combination therapy with nivolumab and tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4371;
Med PFS after addition of nivo to TKI appears similar (N+C) and improved (N+P) compared to nivo monotherapy (Checkmate-025). Med PFS after addition of TKI to IO was also similar (N+C) and improved (N+P) compared to historical controls.
- Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Initially unresectable hepatocellular carcinoma treated by combination therapy of tyrosine kinase inhibitor and anti-PD-1 antibody followed by resection. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4164;
The combination of a TKI and anti-PD-1 antibody is feasible as a conversion therapy. Research Funding: None
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] Genome-wide CRISPR/Cas9 library screening to identify PAK1 as a critical driver for lenvatinib resistance in HCC. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4161;
In summary, our results demonstrate that targeting PAK1 is an effective approach to overcome lenvatinib drug resistance in HCC. Research Funding: None
- [VIRTUAL] Clinical effect of sequential therapy of LEN combination with anti-PD1 antibody in uHCC patients who progressed on LEN treatment: A real-world data in China. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4128;
For advanced patients who have progressed after LEN treatment, the results were promising, showing high DCR and well tolerated. 2 cases even achieve complete response.
- Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Landscape of immune-checkpoint inhibitors in hepatocellular carcinoma: a systematic review with meta-analysis. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4106;
Secondly, nivolumab with ipilimumab were confirmed to provide higher OS in sorafenib progressors as compared to regorafenib. Of note, many of the studies included were only available in abstract form and final reporting is pending.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] Real-world experience of pembrolizumab plus lenvatinib in unresectable hepatocellular carcinoma in Taiwan. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4101;
Such combination could be a promising strategy for unresectable HCC in the future. Research Funding: None
- Opdivo (nivolumab) / Ono Pharma, BMS, Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] Combination therapy with lenvatinib and anti-PD-1 antibodies for unresectable or advanced hepatocellular carcinoma: A real-world study. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4084;
It is also noted that initially unresectable HCC may be converted to resectable HCC following this combination treatment. *, including 6 patients underwent R0 resection.
- leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] Lenvatinib plus hepatic arterial infusion of modified FOLFOX regime in patients with advanced hepatocellular carcinoma. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4077;
A prospective large-scale trial is needed to justify these results. Research Funding: None
- Opdivo (nivolumab) / Ono Pharma, BMS, Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] Safety Run-In Phase (SRP) cohorts 1 and 2 of the IMMUNIB trial (AIO-HEP-0218/ass): An open-label, single-arm phase II study evaluating safety and efficacy of immunotherapy with PD-L1/L2 inhibition (nivolumab) in combination with receptor tyrosine kinase inhibition (lenvatinib) in advanced stage hepatocellular carcinoma (HCC). () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4075;
Regular recruitment was thus opened in January 2020 and is planned to be completed in Q3/2020. Research Funding: Eisai, BMS
- Opdivo (nivolumab) / Ono Pharma, BMS, Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] Real-world experience with Lenvatinib in the management of Hepatocellular Carcinoma: A single-center Indian experience. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4070;
Achieving a PFS of 7 months is an improvement over our previous Sorafenib experience. Further followup will demonstrate the overall survival.
- Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
[VIRTUAL] Safety and efficacy of lenvatinib in HCC beyond second-line treatment. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4066;
Lenvatinib is a promising agent for treating advanced HCC in a later treatment line and revealed a tolerable toxicity profile. Research Funding: None
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD), Calquence (acalabrutinib) / AstraZeneca
[VIRTUAL] FDA’s Oncology Center for Excellence Pilots Project Orbis: A framework for concurrent submission and review of oncology products among international partners. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_3289;
This pilot program facilitates concurrent submission and review of oncology products among global regulatory health agencies. Continued efforts under Project Orbis will build on the initial success to incorporate additional global partners including Swissmedic and Singapore’s Health Science Authority.
- imatinib / Generic mfg., Lenvima (lenvatinib) / Eisai, Merck (MSD), Sutent (sunitinib) / Pfizer
[VIRTUAL] LENVAGIST - A multicenter, comparative, placebo-controlled, double-blinded, phase II study of the efficacy of lenvatinib in patients with locally advanced or metastatic GIST after failure of imatinib and sunitinib. (Poster Board 456) - Apr 29, 2020 - Abstract #ASCO2020ASCO_2588;
P2
Ten participating sites of the French Sarcoma Group will participate in the trial. Research Funding: EISAI
- Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] A Ib/II study of the combination of lenvatinib (L) and eribulin (E) in advanced liposarcoma (LPS) and leiomyosarcoma (LMS) (LEADER). () - Apr 29, 2020 - Abstract #ASCO2020ASCO_2525;
P1/2
L at 14mg/day had a better AE profile without compromising activity. The exploratory biomarker study of LEADER is ongoing.
- BI 836880 / Boehringer Ingelheim, BI 754091 / Boehringer Ingelheim
[VIRTUAL] Phase Ib study of BI 836880, a VEGF/Ang2-blocking nanobody, in combination with BI 754091, an anti-PD-1 antibody: Initial results in patients (pts) with advanced non-small cell lung cancer (NSCLC). (Poster Board 332) - Apr 29, 2020 - Abstract #ASCO2020ASCO_2419;
P1
The combination had a manageable safety profile, and preliminary anti-tumor activity was observed. Expansion cohorts are ongoing.
- letrozole / Generic mfg., Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] Clinical efficacy and molecular effects of lenvatinib (Len) and letrozole (Let) in hormone receptor-positive (HR+) metastatic breast cancer (MBC). (Poster Board 104) - Apr 29, 2020 - Abstract #ASCO2020ASCO_1746;
P2
The results support further investigation in randomized studies. Tumor profiling identified mutations associated with response and insights on molecular effects of lenvatinib.
- Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
[VIRTUAL] Randomized prospective trial assessing Bifidobacterium-containing probiotic supplementation in metastatic renal cell carcinoma (mRCC) patients receiving vascular endothelial growth factor-tyrosine kinase inhibitors (VEGF-TKIs). (Poster Board 147) - Apr 29, 2020 - Abstract #ASCO2020ASCO_1038;
P=N/A
While microbiome modulation by probiotics did not increase CB rates as intended, consecutive stool specimens allowed us to identify an association between B. intesitinihominis, A. municiphila and CB with VEGF-TKIs. In addition to the previously documented association between A. municiphila and immunotherapy outcome (Routy et al.
- Afinitor (everolimus) / Novartis, Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] Quality-adjusted time without symptoms or toxicity (Q-TWiST) of lenvatinib plus everolimus versus everolimus monotherapy in patients with advanced renal cell carcinoma (RCC). (Poster Board 136) - Apr 29, 2020 - Abstract #ASCO2020ASCO_1027;
P1b/2
Within Study 205, lenvatinib+everolimus resulted in a statistically significant and clinically important gain in Q-TWiST vs everolimus alone. Research Funding: Eisai Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
- Afinitor (everolimus) / Novartis, Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
[VIRTUAL] Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes. (Poster Board 132) - Apr 29, 2020 - Abstract #ASCO2020ASCO_1023;
These data provide contemporary benchmarks for OS that may be used for patient counseling and trial design. *Sunitinib, Pazopanib, Cabozantinib †Sunitinib, Pazopanib, Cabozantinib, Axitinib, Lenvatinib NR = Not Reached Research Funding: None
- Keytruda (pembrolizumab) / Merck (MSD), Afinitor (everolimus) / Novartis, Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC). () - Apr 29, 2020 - Abstract #ASCO2020ASCO_969;
P1b/2
No new safety signals were detected. Efficacy outcomes by investigator review per irRECIST.